VXRT
Vaxart, Inc.
0.91
+
0.01
1.27%
1 x 0.90
1 x 0.92
bid
ask
11:11 AM
timesize
Bearish
93
Bullish
293
sentiment
0.88
day range
0.93
0.52
52 week range
1.54
News
...
Does Vaxart Inc (VXRT) offer a good opportunity for investors? | news.google.com • |
Vaxart (NASDAQ:VXRT) Shares Cross Above Two Hundred Day Moving Average of $0.85 | news.google.com • |
VXRT (Vaxart Inc) may reap gains as insiders became active recently | news.google.com • |
Checking in on Travere Therapeutics Inc (TVTX) after recent insiders movement | news.google.com • |
VTLE’s latest rating updates from top analysts. | news.google.com • |
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics | news.google.com • |
Profile
...
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -0.1 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.03 | -0.09 | -0.12 | -400.00% |
2024-05-13 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
2024-03-14 | 2023-12 | -0.15 | -0.12 | 0.03 | 20.00% |
2023-11-02 | 2023-09 | -0.18 | -0.11 | 0.07 | 38.89% |
2023-08-03 | 2023-06 | -0.19 | -0.16 | 0.03 | 15.79% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-12-18 | B. Riley Securities | Upgrade | Neutral | |
2022-09-01 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-05-18 | B. Riley Securities | Upgrade | Neutral | |
2021-11-01 | Cantor Fitzgerald | Upgrade | Overweight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | BERG EDWARD B | General Counsel | 270.71K | Stock Award(Grant) |
2024-03-17 | CUMMINGS JAMES F. | Officer | 330.09K | Stock Award(Grant) |
2024-06-10 | FINNEY MICHAEL J | Director | 686.84K | Stock Award(Grant) |
2024-06-10 | HERON ELAINE J | Director | 40.57K | Stock Award(Grant) |
2024-03-17 | LEE PHILLIP E. | Chief Financial Officer | 241.81K | Stock Award(Grant) |
2024-03-17 | LO STEVEN | Chief Executive Officer | 250.00K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cantor Fitzgerald, L. P. | 7.09M | 5.17M | 4.66% |
2023-06-29 | Vanguard Group Inc | 6.89M | 5.03M | 4.54% |
2023-06-29 | Millennium Management Llc | 2.14M | 1.56M | 1.41% |
2023-06-29 | Blackrock Inc. | 1.93M | 1.41M | 1.27% |
2023-06-29 | Geode Capital Management, LLC | 1.57M | 1.15M | 1.03% |
2023-06-29 | Renaissance Technologies, LLC | 792.01K | 578.16K | 0.52% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.07M | 2.97M | 2.68% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.77M | 1.29M | 1.16% |
2023-05-30 | Fidelity Extended Market Index Fund | 631.59K | 770.54K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 559.90K | 683.08K | 0.37% |
2023-05-30 | Vanguard Health Care Index Fund | 480.63K | 586.37K | 0.32% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 361.97K | 264.24K | 0.24% |
Dividend
...
Dividend | Date |
---|---|
0.1847 | 2012-11-09 |
Split
...
Split | Date |
---|---|
1 : 11 | 2018-02-14 |
0.16667 : 1 | 2012-11-09 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Does Vaxart Inc (VXRT) offer a good opportunity for investors?
news.google.com • -
VXRT (Vaxart Inc) may reap gains as insiders became active recently
news.google.com • -
VTLE’s latest rating updates from top analysts.
news.google.com • -
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics
news.google.com • -
Is Vaxart Inc (VXRT) a good investment opportunity?
news.google.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
seekingalpha.com • -
Vaxart Provides Business Update
globenewswire.com • -
Vaxart Announces $40 Million Underwritten Offering of Common Stock
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
globenewswire.com • -
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
globenewswire.com •